This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print this page

Life Sciences

Life sciences organizations face the challenge of converting great discoveries and research breakthroughs into public acceptance and market success. For companies specializing in pharmaceuticals, biotechnology, medical products and technology and medical devices, the life sciences are changing at a remarkable rate. Deloitte LLP’s Life Sciences practice works with our clients to shape the evolution of the industry. 

Learn more about our Health Sciences practice.

More Featured insights

  • 2014 Global life sciences sector outlook
    The report outlines the top issues facing global life sciences stakeholders, provides a snapshot of activity in a number of geographic markets, and suggests considerations for companies as they seek to grow revenue and market share in 2014 and beyond.
  • The quest for value in health care: A place for consumers
    Three key disrupters are driving an increasingly consumer-centric health care system. How are consumers responding? What are the implications for the industry? And what steps can health care providers, health plans and life sciences companies consider to help win in this new marketplace?
  • Update: Privacy and security of protected health information
    The permanent HIPAA audit program commences in 2014, and the importance of ongoing risk analysis is a central feature of these audits. Industry stakeholders should consider evaluating their HIPAA privacy and security controls as soon as possible.
  • Invigorating biopharma: How the three rules can drive superior performance
    Though changing industry dynamics may call for a focus on cost containment in the short term, biopharma companies can emerge with new strategies that are again oriented toward non-price value and growth.
  • Health care reform: Redefining biopharma innovation
    Health care reform encompasses legislation that has been signed in the recent past related to the access and delivery of healthcare, notably the Affordable Care Act (ACA) passed in 2010, as well as broader, nonreversible trends in the market. Reform culminates into a heightened focus on reducing cost while increasing the quality of care, which will likely force a new definition of innovation to emerge for biopharma.

Join Our Team

Explore Health Sciences career opportunities: Experienced Hires | Students


Stay Updated

Subscribe to receive updates from Deloitte's Life Sciences practice:
Life Sciences Email E-mail |   Life Sciences RSS RSS ( What is RSS?) |  Life Sciences Twitter Twitter 








More Dig Deeper

  • ConvergeHEALTH by Deloitte
    Learn more.
  • 2014 U.S. Outlook on Life Sciences
    Challenges, trends and strategies that may shape your business.
  • Health Care Current library
    A weekly newsletter to keep you informed and ahead.
  • Consulting offerings for the Life Sciences industry
    Helping our clients lead and shape the global marketplace.
  • Deloitte survey of U.S. health care consumers
    Explore the resource library.
  • Deloitte health: Resources, reform, results
    A library of resources.

More Events

  • Financial Times/Deloitte 2014 U.S. Healthcare & Life Sciences Conference
    Join the conversation
  • Harnessing innovation: New strategies for life sciences
    Register for the May 6 webcast.
  • Live from the Center - A look around the corner to 2014: The impact of the ACA implementation
    View the on-demand webinar.
  • Health sciences Dbriefs webcasts library
    Look ahead. Catch up on past events.

Share this page

Email this Send to LinkedIn Send to Facebook Tweet this More sharing options

Stay connected